Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621283 · ClinicalTrials.gov registry record · Phase 1
Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00621283: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00621283 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621283, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic pancreatitis. 3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the pancreatic duct as compared to the non-enhanced MRCP. 4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the duodenum and the apparent diffusion coefficient of the pancreas.
Interventions
- DRUG RG1068 (Synthetic Human Secretin)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2008-02 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621283
The ClinicalTrials.gov registry entry for NCT00621283 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RG1068 (Synthetic Human Secretin) is the first listed.
NCT00621283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621283 about?
NCT00621283 is a clinical study titled "Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population". 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute r...
What is the current status of trial NCT00621283?
This trial is currently terminated. It is a Phase 1 study. The study started on 2008-02. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00621283?
The interventions under investigation include: RG1068 (Synthetic Human Secretin) (DRUG).
Who is sponsoring clinical trial NCT00621283?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.